Whois & Analysis for studentloans.gov

A promissory note, sometimes referred to as a note payable, is a legal instrument (more particularly, a financial instrument, and more specifically a debt instrument), in which one party (the maker or issuer) promises in writing to pay a determinate sum of money to the other (the payee), either at a fixed or determinable future time or on demand of the payee, under specific terms.

If the promissory note is unconditional and readily saleable, it is called a negotiable instrument.

A PLUS Loan is a student loan offered to parents of students enrolled at least half time, or graduate and professional students, at participating and eligible post-secondary institutions.

The original, now obsolete, meaning of the acronym was "Parent Loan for Undergraduate Students".

A student loan is a type of loan designed to help students pay for post-secondary education and the associated fees, such as tuition, books and supplies, and living expenses.

It may differ from other types of loans in that the interest rate may be substantially lower and the repayment schedule may be deferred while the student is still in school.

It also differs in many countries in the strict laws regulating renegotiating and bankruptcy.

This article highlights the differences of the student loan system in several major countries.

In finance, a loan is the lending of money from one individual, organization or entity to another individual, organization or entity.

A loan is a debt provided by an entity (organization or individual) to another entity at an interest rate, and evidenced by a promissory note which specifies, among other things, the principal amount of money borrowed, the interest rate the lender is charging, and date of repayment.

A loan entails the reallocation of the subject asset(s) for a period of time, between the and the .

The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of diseases of the bone marrow in which excess cells are produced.

They are related to, and may evolve into, myelodysplastic syndrome and acute myeloid leukemia, although the myeloproliferative diseases on the whole have a much better prognosis than these conditions.

The concept of myeloproliferative disease was first proposed in 1951 by the hematologist William Dameshek.

In the most recent World Health Organization classification of hematologic malignancies, this group of diseases was renamed from "myeloproliferative diseases" to "myeloproliferative neoplasms".

This reflects the underlying clonal genetic changes that are a salient feature of this group of disease.